

Focused Migraine Interventions Improve the Coordination of Care in a Provider Group Setting

Timothy R. Smith, M.D., R.Ph.¹; Joseph T. Hilgeman, M.D.²; Catherine Wilke, M.D.²; Sally Kane, R.N.¹; Elizabeth P. Skinner, PharmD.³; Mary B. Weaver, R.N.³; Mitzi Corzine¹

¹Mercy Health Research, St. Louis, MO, USA; ²Mercy Medical Group, St. Louis, MO, USA; ³GlaxoSmithKline, Research Triangle Park, NC, USA

Background







- Migraine is a prevalent, painful, disabling and costly condition.
- Despite progress in the understanding of the pathophysiology and recent development of new therapeutic agents, the condition remains both underdiagnosed and undertreated.
- The advent of improved educational effort has been helpful in improving the quality of care of migraine sufferers.
- Demonstrating overall value of a complete program for migraine has not been done effectively to date.

Objective

- The objective of this multi-center study was to demonstrate the overall value of a complete migraine diagnosis and treatment program through a provider group setting.

Design & Methods

- Mercy Medical Group (MMG) is a large primary care group with 120 clinicians and over 200,000 patients.
- Thirty-one physicians and three nurse practitioners from fourteen practice sites in the St. Louis area were educated on the diagnosis and treatment of migraine using tools from:
 - The Ryan Headache Center
 - The Primary Care Network
 - GlaxoSmithKline's Migraine Matrix®, a comprehensive migraine management program.
- Concepts of the program included:
 - impact recognition diagnosis of headache
 - early intervention benefits
 - effective prophylactic schemes
 - non-pharmacologic management
- Assessments conducted at baseline, three months and six months included:
 - headache frequency, pain and severity
 - utilization/productivity
 - HIT-6™
 - Migraine Specific Quality of Life (MSQ) (baseline and six months only)



Results

These results reflect an interim analysis to evaluate the impact of the initiative.

- 283 patients enrolled in the program (24 male, 259 female).
- Data from patients who had completed baseline, three month and six month questionnaires were analyzed.

Patients reported:

- decrease in the number of headache days over the past three months from baseline to six months
- improvement in headache severity from baseline to six months
- significant improvement in HIT-6™ scores from baseline to six months
- decrease in the number of days missed from office, school or house work from baseline to six months
- less worry that headaches are disruptive to daily life from baseline to six months
- increase in satisfaction with care and management of headaches at six months than at baseline.

At six months, a program satisfaction assessment was conducted with the participating physicians and patients. The migraine program received a rating of good to excellent from 95.8% of the providers, while 85.6% of the participants rated the program as good to excellent.

Conclusion

- Interim analyses suggest that a focused migraine intervention conducted in a provider group setting is effective in improving management and outcomes for patients with headaches.

Aknowledgements

Funding provided by:

- GlaxoSmithKline
- Primary Care Network
- Abbott Laboratories